<DOC>
	<DOCNO>NCT00863512</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , vinorelbine , cisplatin , docetaxel , gemcitabine , pemetrexed disodium , work different way stop growth tumor cell , either kill cell stop dividing . Sometimes surgery , tumor may need treatment progress . In case , observation may sufficient . It yet know whether chemotherapy effective observation treat patient undergone surgery stage I non-small cell lung cancer . PURPOSE : This randomized phase III trial study four chemotherapy regimen see well work compare observation treat patient early stage non-small cell lung cancer .</brief_summary>
	<brief_title>Chemotherapy Observation Treating Patients With Early Stage Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine potential overall survival benefit adjuvant chemotherapy patient early stage non-small cell lung cancer ( NSCLC ) randomize chemotherapy compare randomize present standard care ( observation ) . - To collect process high-quality fresh frozen lung cancer tumor tissue gene expression array generation multiple institution . Secondary - To evaluate select genomic-based lung cancer prognostic model use data patient randomized observation resection . - To characterize rate chemotherapy toxicity different chemotherapy treatment regimen . - To assess quality life ( QOL ) early stage patient periodically resection NSCLC . - To examine impact chemotherapy QOL patient receive chemotherapy , compare patient observation arm . OUTLINE : This multicenter study . Patients stratify accord pathologic stage ( I vs II ) ECOG performance status ( 0 vs 1 ) . Patients randomize 1 2 treatment arm within 12 week surgery . All patient undergo complete resection disease ( i.e. , lobectomy , sleeve lobectomy , bi-lobectomy , pneumonectomy , segmentectomy wedge resection ) . - Arm I : Patients receive 1 3 chemotherapy regimen . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . - Regimen 1 : Patients receive vinorelbine ditartrate IV 10 minute day 1 8 cisplatin IV 60 minute day 1 . - Regimen 2 : Patients receive docetaxel IV 60 minute cisplatin IV 60 minute day 1 . - Regimen 3 : Patients receive gemcitabine hydrochloride IV 30 minute day 1 8 cisplatin IV 60 minute day 1 . - Regimen 4 : Patients receive pemetrexed disodium IV 10 minute cisplatin IV 60 minute day 1 . - Arm II : Patients receive standard care ( observation ) . Tissue obtain surgery examine RNA microarray analysis . A Lung Metagene Score ( LMS ) determine patient correlate survival response . After completion study treatment , patient follow every 6 month 5 year year 7 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer Any variant allow ( e.g. , pure mixed bronchioloalveolar carcinoma adenosquamous cell carcinoma ) Primary tumor must T1a , T1b , T2a , T2b AJCC 7.0 No status Tumor measure ≥ 2.0 cm ≤ 7.0 cm diameter CT scan The mass must source document verify tumor size great dimension , include CT scan report , clinic note enrol physician , and/or print image caliper measurement lung mass Nodenegative disease Evidence hilar mediastinal node involvement chest CT scan ( &gt; 1 cm diameter ) must assess mediastinoscopy , endoesophageal ultrasound biopsy , endobronchial ultrasound , bronchoscopy , mediastinal nodal sample time thoracotomy No locally advance metastatic disease PATIENT CHARACTERISTICS : ECOG performance status 01 Granulocytes ≥ 1,500/μL Platelet count ≥ 100,000/μL Bilirubin ≤ 1.5 mg/dL AST &lt; 1.5 time upper limit normal ( ULN ) Serum creatinine ≤ 1.5 time ULN Not pregnant nursing Fertile patient must use effective contraception No history prior concurrent malignancy , except curatively treat carcinoma situ cervix , basal cell squamous cell carcinoma skin , surgically treat situ carcinoma breast , cancer patient diseasefree 3 year PRIOR CONCURRENT THERAPY : More 3 year since prior cytotoxic anticancer treatment No concurrent treatment hormone chemotherapeutic agent , except steroid give adrenal failure , hormone administer nondiseaserelated condition ( e.g. , insulin diabetes ) , intermittent use dexamethasone antiemetic No concurrent thoracic radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>stage IA non-small cell lung cancer</keyword>
	<keyword>stage IB non-small cell lung cancer</keyword>
	<keyword>stage IIA non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
</DOC>